SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, SIAIS562055 enhanced the entry of BCR–ABL inhibitors into CML cells through the upregulation of SLC22A4, followed by the inhibition of ABL phosphorylation and suppression of downstream signaling, which increased the sensitivity of the cells to BCR–ABL inhibitors.